Effect of β-Blocker in Treatment-Naïve Patients With Advanced Lung Adenocarcinoma Receiving First-Generation EGFR-TKIs

Documenti analoghi

• Gefitinib or erlotinib in previously treated non–small‐cell lung cancer patients: a cohort study in Taiwan
  di: Chang, Chia‐Hao, et al.
  Pubblicazione: (2017)
• Including Total EGFR Staining in Scoring Improves EGFR Mutations Detection by Mutation-Specific Antibodies and EGFR TKIs Response Prediction
  di: Wu, Shang-Gin, et al.
  Pubblicazione: (2011)
• Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
  di: Liang, Sheng-Kai, et al.
  Pubblicazione: (2021)
• Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors
  di: Shang-Gin Wu, et al.
  Pubblicazione: (2017-07-01)
• Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors
  di: Wu, Shang-Gin, et al.
  Pubblicazione: (2017)